Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Size: px
Start display at page:

Download "Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry"

Transcription

1 Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet, M Laskar, C Banfi, P Leprince, A Leguerrier, A Prat, and, M Gilard. for the FRANCE2 Registry Investigators

2 Background Diabetes mellitus (DM) is involved in aortic stenosis development and is associated with qualitative changes in valvular tissue (inflammation, metalloproteinase, ) DM has a negative impact on immediate and long term outcome after surgical aortic replacement. While DM is not part of the Euroscore, it has been integrated to the STS score. The impact of DM on post-transcatheter aortic valve replacement (TAVR) outcome is unknown.

3 N=348

4 Objective To compare the outcome of diabetic vs nondiabetic patients, including the primary outcome of the combined occurrence of death and/or stroke in the overall FRANCE2 Registry population and according to device technology and delivery route

5 External database monitoring and quality control was perfroemd in each patients Methods 3195 consecutive patients were prospectivelly enrolled between January 2010 and October 2011 in 34 French centers and included in the FRANCE 2 Registry. Participation of all french centers and inclusion of all patients in France 2 was mandatory by «legal» request. TAVI was performed with a Balloon- or a Self-expandable device TTE was performed at baseline in all patients and before discharge in 2769/3025 (92%) of the eligible population. Peri-valvular AR was graded as none/trivial(=0), mild(=1), moderate(=2), moderate-to-severe(=3), or severe(=4). An AR grade 2 was considered significant.

6 Methods Clinical Follow-up was obtained in all patients at 302 days ±164 days. All adverse events were assessed according to the VARC classification The primary outcome was the combined rate of death and/or stroke at 1 year. Secondary outcomes were: - Post-procedural AR grade2 by TTE; - Device success, - Mortality rates at 30-days and 1-year, - Stroke rates at 30-days and 1-year. - Other VARC periprocedural complications including vascular complication, bleeding, myocardial infarction, and acute kidney injury were also reported.

7 Baseline Clinical Characteristics Diabetics N=797 (25.8%) Non-diabetics N=2298 (74.2%) P Age, years 81.0± ±7.3 < Male 55.3% 49.6% <0.005 BMI, kg/m ± ±4.7 < Hypertension 77.5% 63.7% 0.01 Coronary artery disease, 56.7% 43.0% < History of MI 21.6% 14.0% < Periperal arterial disease 26.8% 17.9% < Renal insuffiencecy 12.2% 8.3% 0.08 Logistique Euroscore 20.4[ ] 19.9[ ] 0.98 STS Score 11.6[ ] 9.6[ ] 0.001

8 Baseline Echocardiography Characteristics Diabetics N=797 (25.8%) Non-diabetics N=2298 (74.2%) P Annulus diameter (pre-procedural TTE) 22.2± ± LVEF, % 52.1± ± Aortic valve area (cm2) 0.68± ± Mean Aortic gradient (mmhg) 45.6± ±17.0 < AR grade 2,n 14.0% 17.8% 0.01 MR grade 2, n 18.3% 21.5% 0.06

9 Procedural Characteristics

10 Combined rate of Death and/or Stroke according to diabetic status 25 Death or stroke, % Unadj.P=0.04 adj. HR=0.62[ ], p=0.01 Non-diabetics Diabetics Days

11 Post-procedural Perivalvular regurgitation grade 2 according to diabetic status % P=0.008 Diabetics Non-diabetics P= P= P= Overall N=3195 N=2138 (66.9%) N=1057 (33.1%) Femoral N=2382 (74.5%) Balloon- Expand. Self- Expand. non- Femoral N=813 (25.4%)

12 Predictors of Perivalvular Aortic Regurgitation Grade 2 : A multivariate analysis Male Gender Diabetes Mellitus MR at baseline AR at baseline Aortic Annulus mm, TTE) Atrial Fibrillation Self Expendable Device Femoral Approach Prosthesis mm increase) Odds ratio p Other parameters in the model are : Age, individual euroscore parameters, BMI, LV ejection fraction, Atrial Fibrillation.

13 Device sucess according to diabetic status % P= P= P= P= P= Diabetics Non-diabetics 70 Overall N=3195 N=2138 (66.9%) N=1057 (33.1%) Femoral N=2382 (74.5%) Balloon- Expand. Self- Expand. non- Femoral N=813 (25.4%)

14 Stroke and Mortality rate according to diabetic status Stroke Mortality Stroke, % P=0.03 Mortality, % P= adj. HR=0.27[ ], p= adj. HR=0.84[ ], p= Days Non-diabetics Days Diabetics

15 Combined rate of Death and/or Stroke Stratified by delivery approach P for interaction= Death or stroke, % Diabetics vs non-diabetics/non-femoral, P=0.001 Diabetics vs non-diabetics/femoral, P=0.67 Non-diabetics/non-femoral Diabetics/non-femoral Non-diabetics/femoral Diabetics/femoral Days

16 Stroke and Mortality rate stratifed by delivery approach Stroke Mortality P for interaction=0.04 P for interaction= Diabetics vs non-diabetics/non-femoral, P=0.006 Diabetics vs non-diabetics/femoral, P= Stroke, % 6 4 Mortality, % Diabetics vs non-diabetics/non-femoral, P=0.02 Diabetics vs non-diabetics/femoral, P= Days Non-diabetics/non-femoral Diabetics/non-femoral Non-diabetics/femoral Diabetics/femoral Days

17 Summary Despite a higher risk profile, diabetic patients with AS undergoing TAVR have a favorable outcome compared to non-diabetic patients. When treated through a femoral approach, diabetics have the similar good outcome than non-diabetic patients. When treated through a non-femoral approach, diabetics do not experience the extra-risk usually associated with this approach.

18 Perspective While the trans-femoral approach must remain the standard approach for non-diabetic patients, a non-femoral approach is a very reasonable alternative in the diabetic population. Considering the high risk associated with the presence of DM in patients with AS undergoing conventional surgical valve replacement, our data suggest that TAVR, including through a non-femoral route, could become the treatment of choice for high-risk diabetic patients with AS. It demonstrates also that DM should not be counted as a negative variable in preprocedural TAVR scores.

19

Anti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry

Anti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry Anti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry Pavel OVERTCHOUK Paul GUEDENEY Stéphanie ROUANET Jean Philippe VERHOYE Thierry LEFEVRE Eric VAN BELLE Helene ELTCHANINOFF Martine

More information

Aortic valve implantation using the femoral and apical access: a single center experience.

Aortic valve implantation using the femoral and apical access: a single center experience. Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany

More information

FRANCE 2 : FRench Aor$c Na$onal Corevalve

FRANCE 2 : FRench Aor$c Na$onal Corevalve : FRench Aor$c Na$onal Corevalve and Edwards Registry Mar$ne Gilard, MD University of Brest, France On behalf of the scien/fic commi2ee and the inves/gators M Laskar, P Donzeau- Gouge, K Chevreul, H Eltchaninoff,

More information

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators

More information

In Process, Unpublished STS/ACC TVT Registry Manuscripts

In Process, Unpublished STS/ACC TVT Registry Manuscripts In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

TAVR IN INTERMEDIATE-RISK PATIENTS

TAVR IN INTERMEDIATE-RISK PATIENTS TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS

More information

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist

More information

TAVI in Rabin Medical Center -

TAVI in Rabin Medical Center - Long-Term Outcomes of 560 Consecutive Patients treated with TAVI and Propensity Score Matched- Analysis of Early Versus New Generation Valves Amos Levi, MD, Uri Landes, MD, Abid R Assali, MD, Katia Orvin,

More information

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI Euro Heart Survey New Programme 2009-2012 Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI Alan Cribier, Rouen, France Andreas Gruentzig Award 2010 Cardiogenic

More information

In Process, Unpublished STS/ACC TVT Registry Manuscripts

In Process, Unpublished STS/ACC TVT Registry Manuscripts In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript

More information

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Maurizio D Amico M.D.

Maurizio D Amico M.D. TAVI BEST CANDIDATE AND OPTIMIZED LONG TERM FOLLOW-UP Maurizio D Amico M.D. Dipartimento Cardiovascolare e Toracico Città della Salute e della Scienza, Turin Italy Regional Guidelines for TAVI implantation

More information

Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience

Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Cardiol Ther (2018) 7:191 196 https://doi.org/10.1007/s40119-018-0115-0 BRIEF REPORT Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Anthony A. Bavry.

More information

1-YEAR OUTCOMES FROM JOHN WEBB, MD

1-YEAR OUTCOMES FROM JOHN WEBB, MD 1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions

More information

Nouvelles indications/ Nouvelles valves

Nouvelles indications/ Nouvelles valves Nouvelles indications/ Nouvelles valves Sadra Lotus Valve system Boston Scientific A. Tirouvanziam Institut Thorax Nantes SH-31314-AC Sept 2012 Slide 1 of 53 SH-31314-AC Sept 2012 Slide 2 of 53 Building

More information

Aortic Stenosis: Background

Aortic Stenosis: Background Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic

More information

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II

More information

For the SURTAVI Investigators

For the SURTAVI Investigators Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter

More information

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40 Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human

More information

Risk Patients Before TAVI or AVR

Risk Patients Before TAVI or AVR Balloon Aortic Valvuloplasty for Highest Risk Patients Before TAVI or AVR Dariusz Dudek Chair of the Board of the Institute of Cardiology Jagiellonian University, Kraków, Poland Chair, Education & Training

More information

Josep Rodés-Cabau, MD, on behalf of the ARTE investigators

Josep Rodés-Cabau, MD, on behalf of the ARTE investigators Versus Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE Randomized Clinical Trial Josep Rodés-Cabau, MD, on behalf

More information

TAVI in Korea, How to Avoid Conduction

TAVI in Korea, How to Avoid Conduction TAVI in Korea, How to Avoid Conduction Disturbance after CoreValve Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul,

More information

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular

More information

Indication, Timing, Assessment and Update on TAVI

Indication, Timing, Assessment and Update on TAVI Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical

More information

Alex versus Xience Registry Preliminary report

Alex versus Xience Registry Preliminary report Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor

More information

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by

More information

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh

More information

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2. Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about

More information

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts

More information

Paravalvular Regurgitation is a Risk Factor Following TAVI

Paravalvular Regurgitation is a Risk Factor Following TAVI Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE

More information

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral

More information

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine

More information

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,

More information

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential

More information

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ

More information

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study 30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL

More information

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators 30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential

More information

The Role of TAVI in high-risk and normal-risk Patients

The Role of TAVI in high-risk and normal-risk Patients The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center

More information

Le TAVI pour tout le monde?

Le TAVI pour tout le monde? Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or

More information

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More? CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology

More information

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy: TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,

More information

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives Transcatheter Aortic Valve Implantation Anaesthetic Prespectives Dr Simon Chan Consultant Department of Anaesthesia and Intensive Care Prince of Wales Hospital Hong Kong 11 Oct 2014 Aortic Stenosis Prevalence

More information

Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment

Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment Stefanos Karagiannis MD PhD Cardiologist Director Echocardiology Dpt Athens Medical Center ESC 2017

More information

Transcatheter aortic valve implantation for aortic stenosis

Transcatheter aortic valve implantation for aortic stenosis NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Transcatheter aortic valve implantation for aortic stenosis Aortic stenosis occurs when the aortic valve

More information

Early Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study

Early Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have

More information

Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke

Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke From the CENTER-Collaboration Wieneke Vlastra, MD Heart Center, Amsterdam UMC, University

More information

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013

More information

Reverse left atrium and left ventricle remodeling after aortic valve interventions

Reverse left atrium and left ventricle remodeling after aortic valve interventions Reverse left atrium and left ventricle remodeling after aortic valve interventions Alexandra Gonçalves, Cristina Gavina, Carlos Almeria, Pedro Marcos-Alberca, Gisela Feltes, Rosanna Hernández-Antolín,

More information

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,

More information

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong 3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease

More information

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado

More information

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Severe left ventricular dysfunction and valvular heart disease: should we operate? Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict

More information

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR

David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS. Peripheral Complications of TAVR David Dexter MD FACS Sentara Vascular Specialists Assistant Professor of Surgery EVMS Peripheral Complications of TAVR TAVR Complications Reported Complications Rates range from 8% to 15% Predictors of

More information

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586 Transcatheter aortic valve implantation for aortic stenosis Interventional procedures guidance Published: 26 July 17 nice.org.uk/guidance/ipg586 Your responsibility This guidance represents the view of

More information

Accepted Manuscript. Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial. Saina Attaran, MD, Vinod H.

Accepted Manuscript. Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial. Saina Attaran, MD, Vinod H. Accepted Manuscript Sixteen Years Later and the Debate for TAVR or SAVR Remains Controversial Saina Attaran, MD, Vinod H. Thourani, MD PII: S0022-5223(18)30624-X DOI: 10.1016/j.jtcvs.2018.02.080 Reference:

More information

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients An STS/ACC TVT Registry Report Howard C. Herrmann, MD University of Pennsylvania Philadelphia Howard C. Herrmann

More information

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University

More information

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

2019 Qualified Clinical Data Registry (QCDR) Performance Measures 2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry

More information

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*

More information

Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI

Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE

More information

7 th Conference of Transcatheter Heart Valve Therapies

7 th Conference of Transcatheter Heart Valve Therapies 7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

Facteurs prédic.fs de mauvais pronos.c à court terme après TAVI

Facteurs prédic.fs de mauvais pronos.c à court terme après TAVI Facteurs prédic.fs de mauvais pronos.c à court terme après TAVI Auffret V., Bedossa M., Donal E., Boulmier D., Laurent M., Mabo P., Verhoye JP., Beneux X., Sost G. et Le Breton H. GRCI 29/11/12 Leon MB

More information

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property

More information

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant

More information

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,

More information

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American

More information

Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation

Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation Prevention and Management of Vascular Complications Related to Transcatheter Aortic Valve Implantation Marco Roffi Division of Cardiology University Hospital Geneva, Switzerland Disclosure Speaker name:...marco

More information

Impact of age on transcatheter aortic valve implantation outcomes: a comparison of patients aged 80 years versus patients > 80 years

Impact of age on transcatheter aortic valve implantation outcomes: a comparison of patients aged 80 years versus patients > 80 years Journal of Geriatric Cardiology (2016) 13: 31 36 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Impact of age on transcatheter aortic valve implantation outcomes: a comparison

More information

TAVI: Nouveaux Horizons

TAVI: Nouveaux Horizons TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La

More information

Corrado Tamburino, MD, PhD

Corrado Tamburino, MD, PhD Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division,

More information

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio

More information

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.

More information

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure Case Report Page 1 of 5 Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure Murat Celik, Uygar Cagdas Yuksel Correspondence to:

More information

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital Oxford I have financial relationships to disclose Honoraria

More information

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat

More information

Edwards' solution for patients suffering from tricuspid valve disease

Edwards' solution for patients suffering from tricuspid valve disease Edwards' solution for patients suffering from tricuspid valve disease R. S. von Bardeleben, MD Head Structural and Heart Valve Center Heart Center Cardiology I, University Medicine Mainz Germany Potential

More information

Transcatheter Aortic Valve Implantation Management of risks and complications

Transcatheter Aortic Valve Implantation Management of risks and complications Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on

More information

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial

More information

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Optimal Imaging Technique Prior to TAVI -Echocardiography- 2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University

More information

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai

More information

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve

More information

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 TAVR Technologies Current Generation Devices ~ 50,000 patients treated thru 2011 in > 500 interventional centers

More information

Role of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money?

Role of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money? Role of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money? Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no

More information

Dr.ssa Loredana Iannetta. Centro Cardiologico Monzino

Dr.ssa Loredana Iannetta. Centro Cardiologico Monzino Dr.ssa Loredana Iannetta Centro Cardiologico Monzino Bicuspid aortic valve BAV is the most common congenital cardiac anomaly. Estimated incidence is 2% in general population. 4:1 male predominance. Frequency

More information

Clinical Outcome in Patients with Aortic Stenosis

Clinical Outcome in Patients with Aortic Stenosis Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,

More information

TAVR SPRING 2017 The evolution of TAVR

TAVR SPRING 2017 The evolution of TAVR TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility

More information

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation

Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation ESC Congress 2010 28 Aug 2010-01 Sep 2010 Stockholm - Sweden Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation Gian Paolo Ussia, MD Director of Interventional

More information

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few

More information

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION ESC CONGRESS HIGHLIGHTS VALVULAR HEART DISEASE AND PULMONARY CIRCULATION N. Ajmone Marsan (Leiden, NL) MD, PhD, FESC Conflicts of Interest None CONTENTS Pulmonary arterial hypertension Rheumatic heart

More information

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?

More information

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Aortic Stenosis - 2011 Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Aortic Surgery Aortic Stenosis EB CT - Ca++ everywhere! Surgery for Aortic Stenosis 100,000 USA + 100,000

More information

VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD

VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Aims of Valve Academic Research Consortium (VARC) (i) selecting appropriate

More information

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular

More information

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.

More information

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences

More information